Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2009

01.11.2009 | Epidemiology

Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast

verfasst von: DeShawn Taylor, Celeste Leigh Pearce, Linda Hovanessian-Larsen, Susan Downey, Darcy V. Spicer, Sue Bartow, Malcolm C. Pike, Anna H. Wu, Debra Hawes

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

We report here our studies of nuclear staining for the progesterone and estrogen receptors (PRA, PRB, ERα) and cell proliferation (MIB1) in the breast terminal duct lobular unit epithelium of 26 naturally cycling premenopausal women and 30 pregnant women (median 8.1 weeks gestation). Square root transformations of the PRA, PRB and ERα values, and a logarithmic transformation of the MIB1 values, were made to achieve more normal distributions of the values. PRA expression decreased from a mean of 17.8% of epithelial cells in cycling subjects to 6.2% in pregnant subjects (P = 0.013). MIB1 expression increased from 1.7% in cycling subjects to 16.0% in pregnant subjects (P < 0.001). PRB and ERα expression was slightly lower in pregnant subjects but the differences were not statistically significant. Sixteen of the non-pregnant subjects were nulliparous and ten were parous so that we had limited power to detect changes associated with parity. PRA was statistically significantly lower in parous women than in nulliparous women (32.2% in nulliparous women vs. 10.2%; P = 0.014). PRB (23.5 vs. 12.9%), ERα (14.4 vs. 8.6%) and MIB1 (2.2 vs. 1.2%) were also lower in parous women, but the differences were not statistically significant. The marked decreases in PRA in pregnancy and in parous women has also been found in the rat. A reduction in PRA expression may be a useful marker of the reduction in risk with pregnancy and may be of use in evaluating the effect of any chemoprevention regimen aimed at mimicking pregnancy. Short-term changes in PRA expression while the chemoprevention is being administered may be a more useful marker.
Literatur
1.
Zurück zum Zitat Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O’Malley BW, McDonnell DP (1993) Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7:1244–1255. doi:10.1210/me.7.10.1244 CrossRefPubMed Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O’Malley BW, McDonnell DP (1993) Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7:1244–1255. doi:10.​1210/​me.​7.​10.​1244 CrossRefPubMed
3.
Zurück zum Zitat Aupperlee MD, Smith KT, Kariagina A, Haslam SZ (2005) Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology 146:3577–3588. doi:10.1210/en.2005-0346 CrossRefPubMed Aupperlee MD, Smith KT, Kariagina A, Haslam SZ (2005) Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology 146:3577–3588. doi:10.​1210/​en.​2005-0346 CrossRefPubMed
6.
Zurück zum Zitat Taylor CR, Shi SR, Chen C, Young L, Yang C, Cote RJ (1996) Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotech Histochem 71:263–270. doi:10.3109/10520299609117171 CrossRefPubMed Taylor CR, Shi SR, Chen C, Young L, Yang C, Cote RJ (1996) Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotech Histochem 71:263–270. doi:10.​3109/​1052029960911717​1 CrossRefPubMed
9.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2004) Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 with breast cancer from 16 countries. Lancet 363:1007–1016. doi:10.1016/S0140-6736(04)15835-2 CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2004) Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 with breast cancer from 16 countries. Lancet 363:1007–1016. doi:10.​1016/​S0140-6736(04)15835-2 CrossRef
10.
12.
Zurück zum Zitat Speirs V, Skliris GP, Burdall SE, Carder PJ (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55:371–374PubMed Speirs V, Skliris GP, Burdall SE, Carder PJ (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55:371–374PubMed
14.
Zurück zum Zitat Petersen OW, Hoyer PE, van Deurs B (1987) Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 47:5748–5751PubMed Petersen OW, Hoyer PE, van Deurs B (1987) Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 47:5748–5751PubMed
15.
Zurück zum Zitat Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987–4991PubMed Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987–4991PubMed
17.
Zurück zum Zitat Jacquemier JD, Hassoun J, Torrente M, Martin P-M (1990) Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages-Immunohistochemical study of 107 cases. Breast Cancer Res Treat 15:109–117. doi:10.1007/BF01810783 CrossRefPubMed Jacquemier JD, Hassoun J, Torrente M, Martin P-M (1990) Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages-Immunohistochemical study of 107 cases. Breast Cancer Res Treat 15:109–117. doi:10.​1007/​BF01810783 CrossRefPubMed
18.
Zurück zum Zitat Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, Potten CS (1991) Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 48:206–210. doi:10.1002/ijc.2910480209 CrossRefPubMed Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, Potten CS (1991) Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 48:206–210. doi:10.​1002/​ijc.​2910480209 CrossRefPubMed
19.
Zurück zum Zitat Battersby S, Robertson BJ, Anderson TJ, King RJB, McPherson K (1992) Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer 65:601–607PubMed Battersby S, Robertson BJ, Anderson TJ, King RJB, McPherson K (1992) Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer 65:601–607PubMed
20.
Zurück zum Zitat Söderqvist G, von Schoultz B, Tani E, Skoog L (1993) Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 168:874–879PubMed Söderqvist G, von Schoultz B, Tani E, Skoog L (1993) Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 168:874–879PubMed
21.
Zurück zum Zitat Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217–227. doi:10.1023/A:1006186719322 CrossRefPubMed Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217–227. doi:10.​1023/​A:​1006186719322 CrossRefPubMed
22.
Zurück zum Zitat Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC (2006) Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res 8:R6. doi:10.1186/bcr1367 CrossRefPubMed Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC (2006) Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res 8:R6. doi:10.​1186/​bcr1367 CrossRefPubMed
23.
Zurück zum Zitat Battersby S, Anderson TJ (1988) Proliferative and secretory activity in the pregnant and lactating human breast. Virchows Archiv A Pathol Anat 413:189–196CrossRef Battersby S, Anderson TJ (1988) Proliferative and secretory activity in the pregnant and lactating human breast. Virchows Archiv A Pathol Anat 413:189–196CrossRef
25.
Zurück zum Zitat Olsson H, Jernström H, Alm P, Kreipe H, Ingvar C, Jönsson PE, Rydén S (1996) Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. Breast Cancer Res Treat 40:187–196. doi:10.1007/BF01806214 CrossRefPubMed Olsson H, Jernström H, Alm P, Kreipe H, Ingvar C, Jönsson PE, Rydén S (1996) Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. Breast Cancer Res Treat 40:187–196. doi:10.​1007/​BF01806214 CrossRefPubMed
28.
Zurück zum Zitat Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, Potten CS (1991) Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 48:206–210. doi:10.1002/ijc.2910480209 CrossRefPubMed Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, Potten CS (1991) Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 48:206–210. doi:10.​1002/​ijc.​2910480209 CrossRefPubMed
29.
Zurück zum Zitat Feuerhake F, Sigg W, Höfter EA, Unterberger P, Welsch U (2003) Cell proliferation, apoptosis, and expression of Bcl-2 and Bax in non-lactating human breast epithelium in relation to the menstrual cycle and reproductive history. Breast Cancer Res Treat 77:37–48. doi:10.1023/A:1021119830269 CrossRefPubMed Feuerhake F, Sigg W, Höfter EA, Unterberger P, Welsch U (2003) Cell proliferation, apoptosis, and expression of Bcl-2 and Bax in non-lactating human breast epithelium in relation to the menstrual cycle and reproductive history. Breast Cancer Res Treat 77:37–48. doi:10.​1023/​A:​1021119830269 CrossRefPubMed
30.
Zurück zum Zitat Joshi K, Smith JA, Perusinghe N, Monoghan P (1986) Cell proliferation in the human mammary epithelium. Am J Pathol 124:199–206PubMed Joshi K, Smith JA, Perusinghe N, Monoghan P (1986) Cell proliferation in the human mammary epithelium. Am J Pathol 124:199–206PubMed
31.
Zurück zum Zitat Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, kConfab Investigators, Kirk JA, Clarke CL (2004) Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer 39:236–248. doi:10.1002/gcc.10321 CrossRefPubMed Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, kConfab Investigators, Kirk JA, Clarke CL (2004) Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer 39:236–248. doi:10.​1002/​gcc.​10321 CrossRefPubMed
33.
Zurück zum Zitat Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH, Dale E (1998) Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci USA 95:696–701. doi:10.1073/pnas.95.2.696 CrossRefPubMed Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH, Dale E (1998) Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci USA 95:696–701. doi:10.​1073/​pnas.​95.​2.​696 CrossRefPubMed
34.
Zurück zum Zitat Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL (1995) Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55:5063–5068PubMed Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL (1995) Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55:5063–5068PubMed
Metadaten
Titel
Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast
verfasst von
DeShawn Taylor
Celeste Leigh Pearce
Linda Hovanessian-Larsen
Susan Downey
Darcy V. Spicer
Sue Bartow
Malcolm C. Pike
Anna H. Wu
Debra Hawes
Publikationsdatum
01.11.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0322-4

Weitere Artikel der Ausgabe 1/2009

Breast Cancer Research and Treatment 1/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.